US-based technology company, Heru, has launched re:Vive 2.0, which expands on the capabilities of the original wearable diagnostic headset. The updated version adds three new testing modalities – colour vision, contrast sensitivity and dark adaptation testing – to the existing functions.
The colour vision testing feature, used for the detection of inherited or acquired eye diseases, uses the Ishihara colour vision test and the Farnsworth D-15 extended colour vision test. Meanwhile, contrast sensitivity, for documenting and monitoring macular health, helps provide tangible proof of the slow-changing effects of diminishing vision.
The new modalities aim to expand practice capabilities and increase the opportunity to boost revenue with a free cloud-based upgrade
In addition, the dark adaptation modality allows practitioners to evaluate the retinal function to detect the early signs and symptoms of age-related macular degeneration. The software replaces the need for traditional testing, presenting a more affordable option.
The new modalities aim to expand practice capabilities and increase the opportunity to boost revenue. Delivered to the existing platform remotely, the free software upgrade will not be disruptive and will enable practitioners to treat more patients with a multi-modal cloud-based platform utilising existing CPT codes.
Heru demonstrated the re:Vive 2.0 technology at the 2021 American Academy of Optometry Annual Meeting (3-5 November).